Rezzayo: payments to doctors
Payments that named Rezzayo as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $906K
- Providers
- 3,248
- Transactions
- 9,612
- Average per transaction
- $94
The per-transaction average — $94 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,248 providers the average total is $279, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Melinta Therapeutics, LLC | $887,132 | 97.9% |
| Cidara Therapeutics, Inc. | $19,188 | 2.1% |